Medtronic Trial for AFib System Achieves Endpoints
By Ben Glickman
Medtronic said its combined system for use during treatment of atrial fibrillation reached its safety and efficacy endpoints in a trial.
The medical-device company said that the Affera Mapping and Ablation System with Sphere-9 Catheter, an ablation and mapping system, showed higher freedom from AFib compared with the control arm of the trial and had a comparable safety profile.
The Affera system with Sphere-9 catheter was specifically being evaluated in cases of persistent AFib, which makes up 30% to 50% of patients.
The company said it had recently filed for approval of the combined system in the U.S.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 17, 2024 17:03 ET (21:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now